COVID-19 infection and renin angiotensin system blockers

April 03, 2020

What The Viewpoint Says: Discussion of recommendations for angiotensin-converting enzyme inhibitor and angiotensin receptor blocker use in patients with or at risk of contracting coronavirus disease 2019 (COVID-19).

Authors: Franz H. Messerli, M.D., of Bern University Hospital in Switzerland, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ 

(doi:10.1001/jamacardio.2020.1282)

Editor's Note: Please see the articles for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.
-end-
Media advisory: The full article is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2020.1282?guestAccessKey=e7664282-d295-4d2f-9c47-dc723f53ac67&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=040320

JAMA Cardiology

Related Angiotensin Articles from Brightsurf:

Graz researchers identify biomarker for cardiovascular diseases
The role of the enzyme dipeptidyl peptidase 3 in the blood pressure-regulating renin-angiotensin system was investigated in the inter-university cooperation project BioTechMed-Graz.

Existing heart drugs may help cancer patients respond better to PD(L)1 immunotherapy
Researchers have found that a class of commonly-used heart drugs may also improve patients' responses to anti-cancer immunotherapies called PD(L)1 inhibitors, according to preliminary findings to be presented at the 32th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, which is taking place online.

Users of blood pressure medicine have a lower risk of dying from influenza and pneumonia
Thousands of Danes use ACE inhibitors or angiotensin II receptor blockers against elevated blood pressure or heart problems, and they may have an improved chance of surviving severe influenza or pneumonia infections.

Study leads to better understanding of blood pressure regulation, atherosclerosis
A new University of Kentucky College of Medicine study provides insight into how a protein called angiotensinogen contributes to blood pressure regulation and atherosclerosis.

Blood pressure medication improves COVID-19 survival rates
New research finds that medication for high blood pressure could improve Covid-19 survival rates and reduce the severity of infection.

New diagnostic test for heart failure patients could also help COVID-19 patients
A new blood test that reliably predicts outcomes for heart failure patients could lead to new diagnostics and treatments for COVID-19 patients as well, according to newly published research from cardiologists at the University of Alberta.

Association of use of ACEI, ARB with testing positive for COVID-19
This observational study assessed the association between the use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with the likelihood of testing positive for coronavirus disease 2019 (COVID-19).

Study finds high blood pressure medications safe for patients with COVID-19 disease
Despite concerns expressed by some experts, common high blood pressure drugs did not increase the risk of contracting COVID-19 -- or of developing severe disease -- in a study of 12,594 patients.

Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for COVID-19
The association between angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and the severity of illness and death in patients with hypertension hospitalized for COVID-19 is examined in this study.

COVID-19 infection and renin angiotensin system blockers
Discussion of recommendations for angiotensin-converting enzyme inhibitor and angiotensin receptor blocker use in patients with or at risk of contracting coronavirus disease 2019 (COVID-19).

Read More: Angiotensin News and Angiotensin Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.